Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
PURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye. STUDY DESIGN: This was a comparative, prospective, interventional study. PATIENTS AND METHODS: A total of 140 patients...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Taiwan Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=173;epage=178;aulast=Singla |
| _version_ | 1818873958200508416 |
|---|---|
| author | Shaveta Singla Lopamudra Sarkar Mukesh Joshi |
| author_facet | Shaveta Singla Lopamudra Sarkar Mukesh Joshi |
| author_sort | Shaveta Singla |
| collection | DOAJ |
| description | PURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye.
STUDY DESIGN: This was a comparative, prospective, interventional study.
PATIENTS AND METHODS: A total of 140 patients diagnosed with moderate dry eyes were randomly divided into two groups. Group A patients received treatment with topical loteprednol 0.5% started as QID dosage for 2 weeks and tapered to BID dosage over the next 6 weeks, topical Cs 0.05% BID and artificial tears. Group B patients received treatment with topical Cs 0.05% BID and artificial tears. All patients were followed over a period of 6 months with ocular surface disease index (OSDI) questionnaire, tear film break up time (TBUT), corneal fluorescein, and lissamine green staining scores.
RESULTS: There was a significant difference in the symptoms and signs of dry eye in the group receiving combination of loteprednol 0.5% and Cs 0.05% as compared to the group receiving Cs alone evident by greater reduction in OSDI score, corneal staining, and improvement in TBUT and Schirmer's test values over a follow-up of 6 months.
CONCLUSION: Combination therapy with topical loteprednol and Cs is significantly better than topical Cs alone on alleviating symptoms and signs in moderate dry eye patients. |
| first_indexed | 2024-12-19T13:02:58Z |
| format | Article |
| id | doaj.art-0893fcff70fd4dc98ee4eb6274b9a05d |
| institution | Directory Open Access Journal |
| issn | 2211-5056 2211-5072 |
| language | English |
| last_indexed | 2024-12-19T13:02:58Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Taiwan Journal of Ophthalmology |
| spelling | doaj.art-0893fcff70fd4dc98ee4eb6274b9a05d2022-12-21T20:20:10ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722019-01-019317317810.4103/tjo.tjo_15_18Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective studyShaveta SinglaLopamudra SarkarMukesh JoshiPURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye. STUDY DESIGN: This was a comparative, prospective, interventional study. PATIENTS AND METHODS: A total of 140 patients diagnosed with moderate dry eyes were randomly divided into two groups. Group A patients received treatment with topical loteprednol 0.5% started as QID dosage for 2 weeks and tapered to BID dosage over the next 6 weeks, topical Cs 0.05% BID and artificial tears. Group B patients received treatment with topical Cs 0.05% BID and artificial tears. All patients were followed over a period of 6 months with ocular surface disease index (OSDI) questionnaire, tear film break up time (TBUT), corneal fluorescein, and lissamine green staining scores. RESULTS: There was a significant difference in the symptoms and signs of dry eye in the group receiving combination of loteprednol 0.5% and Cs 0.05% as compared to the group receiving Cs alone evident by greater reduction in OSDI score, corneal staining, and improvement in TBUT and Schirmer's test values over a follow-up of 6 months. CONCLUSION: Combination therapy with topical loteprednol and Cs is significantly better than topical Cs alone on alleviating symptoms and signs in moderate dry eye patients.http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=173;epage=178;aulast=SinglaCyclosporineloteprednolmoderate dry eyeocular surface disease index score |
| spellingShingle | Shaveta Singla Lopamudra Sarkar Mukesh Joshi Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study Taiwan Journal of Ophthalmology Cyclosporine loteprednol moderate dry eye ocular surface disease index score |
| title | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| title_full | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| title_fullStr | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| title_full_unstemmed | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| title_short | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| title_sort | comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in indian population a prospective study |
| topic | Cyclosporine loteprednol moderate dry eye ocular surface disease index score |
| url | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=3;spage=173;epage=178;aulast=Singla |
| work_keys_str_mv | AT shavetasingla comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy AT lopamudrasarkar comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy AT mukeshjoshi comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy |